Biofarm (BIO) Stock Overview
Manufactures and sells medicines in Romania. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for BIO from our risk checks.
BIO Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Biofarm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RON 1.30 |
| 52 Week High | RON 1.36 |
| 52 Week Low | RON 0.62 |
| Beta | 0.51 |
| 1 Month Change | 17.12% |
| 3 Month Change | 57.00% |
| 1 Year Change | 86.25% |
| 3 Year Change | 100.00% |
| 5 Year Change | 128.07% |
| Change since IPO | 236.11% |
Recent News & Updates
Recent updates
Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Mar 18
Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?
Feb 18
Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return
Jan 23A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)
Dec 25Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?
Dec 03Shareholder Returns
| BIO | RO Pharmaceuticals | RO Market | |
|---|---|---|---|
| 7D | 0.8% | -2.0% | 3.4% |
| 1Y | 86.2% | -2.6% | 51.7% |
Return vs Industry: BIO exceeded the RO Pharmaceuticals industry which returned -2.6% over the past year.
Return vs Market: BIO exceeded the RO Market which returned 51.7% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in RO Market | 10.4% |
| 10% least volatile stocks in RO Market | 3.2% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months compared to the RO market.
Volatility Over Time: BIO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1921 | 367 | Catalin Vicol | www.biofarm.ro |
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescription medicines, food supplements, medical devices, cosmetics, and other products.
Biofarm S.A. Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | RON 1.28b |
| Earnings (TTM) | RON 100.82m |
| Revenue (TTM) | RON 319.33m |
Is BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | RON 319.33m |
| Cost of Revenue | RON 46.03m |
| Gross Profit | RON 273.30m |
| Other Expenses | RON 172.49m |
| Earnings | RON 100.82m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 15, 2026
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 85.59% |
| Net Profit Margin | 31.57% |
| Debt/Equity Ratio | 0.2% |
How did BIO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/16 15:06 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biofarm S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Raluca Florea | Erste Group Bank AG |